新诊断急性髓系白血病中标准或高剂量柔红霉素联合7+3方案的单次或双次诱导:研究联盟白血病随机DaunoDouble试验
该随机对照试验纳入864例18-65岁新诊断AML患者,比较首次7+3诱导中柔红霉素60 mg/m2与90 mg/m2每日一次,以及1个与2个7+3诱导周期。结果显示90 mg/m2较60 mg/m2未显著改善早期反应、缓解率或生存;首次诱导后早期反应良好者,第二次诱导对无复发生存影响有限且未带来总生存获益。
要点
- 柔红霉素90 mg/m2每日一次较60 mg/m2每日一次未显著改善早期反应、缓解率或生存。
- 首次诱导后早期反应良好者,第二次诱导对无复发生存影响有限且无总生存获益。
- 首次诱导后骨髓原始细胞低于5%的患者被随机分配接受或不接受第二次诱导。
核心结论
- 在经典7+3诱导中,柔红霉素90 mg/m2每日一次较60 mg/m2每日一次未显著改善早期反应,未带来更高缓解率或更长生存。
- 首次诱导后早期反应良好的患者,第二次诱导对无复发生存影响有限,未带来总生存获益。
研究设计与样本
- 随机对照试验,纳入18-65岁新诊断AML患者,随机分配至柔红霉素60 mg/m2或90 mg/m2每日一次联合阿糖胞苷。
- 首次诱导后第15天骨髓原始细胞低于5%的患者,随机分配接受或不接受第二次诱导周期。
- 共864例患者随机分配,中位年龄52岁。
主要发现
- 预设中期分析显示60 mg/m2与90 mg/m2反应无显著差异后,所有后续患者接受柔红霉素60 mg/m2每日一次。
- 良好早期反应者比例60 mg/m2组为44% vs 90 mg/m2组为48%(P = .983)。
- 诱导后复合完全缓解(CRc)率60 mg/m2组为90% vs 90 mg/m2组为89%(P = .691)。
- 3年无复发生存(RFS)60 mg/m2组为54% vs 90 mg/m2组为50%(P = .561),3年总生存(OS)60 mg/m2组为65% vs 90 mg/m2组为58%(P = .242)。
- 389例良好反应者中,诱导结束时CRc率单次诱导为87% vs 双次诱导为85%;3年RFS单次诱导为51% vs 双次诱导为60%(风险比[HR] 1.3;P = .091),3年OS单次诱导为76% vs 双次诱导为75%(HR 1.0;P = .937)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine the optimal daunorubicin dose and number of 7 + 3 induction cycles in newly diagnosed AML, this randomized controlled trial compared a once daily dose of 60 mg/m2 with 90 mg/m2 daunorubicin in the first 7 + 3 induction and one versus two cycles of 7 + 3 induction. PATIENTS AND METHODS: Patients age 18-65 years with newly diagnosed AML were randomly assigned to 60 versus 90 mg/m2 daunorubicin once daily plus cytarabine. Patients with marrow blasts below 5% on day 15 after first induction were randomly assigned to receive a second induction cycle or no second induction cycle. RESULTS: Eight hundred and sixty-four patients with a median age of 52 years were randomly assigned. After a preplanned interim analysis showing no significant difference in response between 60 and 90 mg/m2, all consecutive patients received 60 mg/m2 daunorubicin once daily. The proportion of good early responders was 44% versus 48% (P = .983) with a composite complete remission (CRc) rate of 90% versus 89% after induction (P = .691); the 3-year relapse-free survival (RFS) after 60 versus 90 mg/m2 once daily was 54% versus 50% (P = .561), and the 3-year overall survival (OS) was 65% versus 58% (P = .242). Among 389 good responders, CRc rates at the end of induction were 87% after single induction and 85% after double induction. The 3-year RFS was 51% versus 60% (hazard ratio [HR], 1.3; P = .091), and the 3-year OS was 76% versus 75% after single versus double induction (HR, 1.0; P = .937). CONCLUSION: The use of 90 mg/m2 daunorubicin once daily in the context of classical 7 + 3 induction does not significantly improve early response and does not lead to higher remission rates or longer survival than 60 mg/m2 once daily. In patients with a good early response after first induction, a second induction has only a limited impact on RFS and does not result in an OS benefit.
引用
- Röllig C, Steffen B, Schliemann C, et al. Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia. J Clin Oncol. 2024. PMID: 39284116. doi:10.1200/JCO.24.00235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。